A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)

Objective. To evaluate the efficacy and safety of Yi Qi Gu Biao (YQGB) pill in treating frequent exacerbator phenotype in chronic obstructive pulmonary disease (lung and spleen qi deficiency syndrome) (FEPCOPD). Methods. This prospective, randomized, double-blind, controlled study assessed 112 cases...

Full description

Bibliographic Details
Main Authors: Gao Zhen, Jing Jing, Xu Dan, Li Zheng, Li Fengsen, Sun Qi
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Evidence-Based Complementary and Alternative Medicine
Online Access:http://dx.doi.org/10.1155/2017/9130804
id doaj-df8e4ebfaa4646ffb192ef2bdb6e0df8
record_format Article
spelling doaj-df8e4ebfaa4646ffb192ef2bdb6e0df82020-11-24T23:03:38ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882017-01-01201710.1155/2017/91308049130804A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)Gao Zhen0Jing Jing1Xu Dan2Li Zheng3Li Fengsen4Sun Qi5National Clinical Research Base of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, ChinaNational Clinical Research Base of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, ChinaNational Clinical Research Base of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, ChinaNational Clinical Research Base of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, ChinaNational Clinical Research Base of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, ChinaNational Clinical Research Base of Traditional Chinese Medicine, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, ChinaObjective. To evaluate the efficacy and safety of Yi Qi Gu Biao (YQGB) pill in treating frequent exacerbator phenotype in chronic obstructive pulmonary disease (lung and spleen qi deficiency syndrome) (FEPCOPD). Methods. This prospective, randomized, double-blind, controlled study assessed 112 cases (64 included) of FEPCOPD treated at the outpatient department in our hospital in January–August 2016. The patients were randomly divided into YQGB and placebo (Pb) and treated for three months. Lung function, CAT, mMRC, and TCM symptom scores (TCMs) were observed. Results. Compared with Pb, YQGB showed decreased wheezing symptom scores (WSs) and TCMs at one month and decreased CAT and TCMs at three months. From one to three months, CAT, cough, sputum, WSs, and TCMs in YQGB were lower than pretreatment values. But in Pb, CAT was lower than pretreatment values after one month; CAT, sputum, and TCMs were lower than pretreatment values after two months; CAT, cough, sputum, WSs, and TCMs were lower than pretreatment values after three months. Conclusion. Yi Qi Gu Biao pill can improve wheezing, health status, and TCMs in FEPCOPD and also can shorten the durations of cough, sputum, and wheezing. This trial is registered in the Clinical Trials Registry of China: ChiCTR-IOR-15007542 (on 8 December 2015).http://dx.doi.org/10.1155/2017/9130804
collection DOAJ
language English
format Article
sources DOAJ
author Gao Zhen
Jing Jing
Xu Dan
Li Zheng
Li Fengsen
Sun Qi
spellingShingle Gao Zhen
Jing Jing
Xu Dan
Li Zheng
Li Fengsen
Sun Qi
A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)
Evidence-Based Complementary and Alternative Medicine
author_facet Gao Zhen
Jing Jing
Xu Dan
Li Zheng
Li Fengsen
Sun Qi
author_sort Gao Zhen
title A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)
title_short A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)
title_full A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)
title_fullStr A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)
title_full_unstemmed A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)
title_sort randomized controlled study of the yi qi gu biao pill in the treatment of frequent exacerbator phenotype in chronic obstructive pulmonary disease (lung and spleen qi deficiency syndrome)
publisher Hindawi Limited
series Evidence-Based Complementary and Alternative Medicine
issn 1741-427X
1741-4288
publishDate 2017-01-01
description Objective. To evaluate the efficacy and safety of Yi Qi Gu Biao (YQGB) pill in treating frequent exacerbator phenotype in chronic obstructive pulmonary disease (lung and spleen qi deficiency syndrome) (FEPCOPD). Methods. This prospective, randomized, double-blind, controlled study assessed 112 cases (64 included) of FEPCOPD treated at the outpatient department in our hospital in January–August 2016. The patients were randomly divided into YQGB and placebo (Pb) and treated for three months. Lung function, CAT, mMRC, and TCM symptom scores (TCMs) were observed. Results. Compared with Pb, YQGB showed decreased wheezing symptom scores (WSs) and TCMs at one month and decreased CAT and TCMs at three months. From one to three months, CAT, cough, sputum, WSs, and TCMs in YQGB were lower than pretreatment values. But in Pb, CAT was lower than pretreatment values after one month; CAT, sputum, and TCMs were lower than pretreatment values after two months; CAT, cough, sputum, WSs, and TCMs were lower than pretreatment values after three months. Conclusion. Yi Qi Gu Biao pill can improve wheezing, health status, and TCMs in FEPCOPD and also can shorten the durations of cough, sputum, and wheezing. This trial is registered in the Clinical Trials Registry of China: ChiCTR-IOR-15007542 (on 8 December 2015).
url http://dx.doi.org/10.1155/2017/9130804
work_keys_str_mv AT gaozhen arandomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT jingjing arandomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT xudan arandomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT lizheng arandomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT lifengsen arandomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT sunqi arandomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT gaozhen randomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT jingjing randomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT xudan randomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT lizheng randomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT lifengsen randomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
AT sunqi randomizedcontrolledstudyoftheyiqigubiaopillinthetreatmentoffrequentexacerbatorphenotypeinchronicobstructivepulmonarydiseaselungandspleenqideficiencysyndrome
_version_ 1725632954503266304